Loading
Two new relapsed-disease options with different targets and mechanisms. Which comes first, and whether one works after the other, is unknown.
This sequencing question in relapsed small-cell lung cancer concerns tarlatamab, a DLL3-directed T-cell engager, and ifinatamab deruxtecan (I-DXd), a B7-H3-directed antibody-drug conjugate with a topoisomerase 1 payload. Tarlatamab has shown a survival benefit in DeLLphi-304, while I-DXd has produced high response rates and is in the phase 3 IDeate-Lung02 trial. Because the two drugs hit different antigens and kill by different mechanisms, they are expected not to be cross-resistant, and their toxicity profiles also differ, cytokine release syndrome for one and interstitial lung disease and neutropenia for the other, which could allow a patient-based choice. No prospective data yet say which should come first or whether one works after the other, so the pairing remains a concept.
Shares B7-H3, Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Ifinatamab deruxtecan, DLL3, Tarlatamab, Extensive-stage small-cell lung cancer.
Shares B7-H3, Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares DLL3, Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Small-cell lung cancer.